Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis
ObjectiveTo compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.MethodsWe retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity...
Main Authors: | Xuemei Tao, Changjing Xu, Xiaoyan Zhong, Yao Mou, Jingwei Li, Xuping Yang, Yilan Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.1047595/full |
Similar Items
-
Pharmacokinetics of biapenem in critically ill patients
by: Zyryanov S.K., et al.
Published: (2023-09-01) -
Biapenem, a Carbapenem Antibiotic, Elicits Mycobacteria Specific Immune Responses and Reduces the Recurrence of Tuberculosis
by: Isha Pahuja, et al.
Published: (2023-08-01) -
Studies on the Reactions of Biapenem with VIM Metallo β-Lactamases and the Serine β-Lactamase KPC-2
by: Anka Lucic, et al.
Published: (2022-03-01) -
Clinical features and risk factors analysis for poor outcomes of severe community-acquired pneumonia in children: a nomogram prediction model
by: Changjing Xu, et al.
Published: (2023-09-01) -
Predictive Value of Lysophosphatidylcholine for Determining the Disease Severity and Prognosis of Elderly Patients with Community-Acquired Pneumonia
by: Gu M, et al.
Published: (2024-03-01)